Compare EARN & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EARN | ACOG |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 193.6M |
| IPO Year | 2012 | 2024 |
| Metric | EARN | ACOG |
|---|---|---|
| Price | $4.32 | $8.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.38 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 356.2K | 162.7K |
| Earning Date | 06-16-2026 | 05-14-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,220,275.00 |
| Revenue This Year | $7.69 | $139.22 |
| Revenue Next Year | $19.57 | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $4.50 |
| 52 Week High | $5.77 | $10.14 |
| Indicator | EARN | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 47.57 |
| Support Level | $4.29 | $5.28 |
| Resistance Level | $4.49 | $9.04 |
| Average True Range (ATR) | 0.07 | 0.55 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 2.38 | 3.91 |
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.